创新医疗器械盘点系列（4）：肿瘤基因检测的勇敢者游戏（上篇）

Investment Rating - The report maintains an "Outperform" rating for the tumor gene testing industry [1] Core Insights - The tumor gene testing industry is on a fast development track, with significant international transactions and domestic regulatory innovations occurring since Q4 2025. The market is expected to expand significantly as applications for tumor MRD and multi-cancer early screening mature [2][6] - Exact Sciences is a leading company in colorectal cancer screening, projecting revenues of $3.22 to $3.235 billion for 2025, representing a growth of 16.7% to 17.2%. The company aims for a compound annual growth rate (CAGR) of 15% from 2022 to 2027 [2][18] - Natera is recognized as a leader in minimal residual disease (MRD) testing, with its core product, Signatera, achieving a sample volume of over 200,000 in Q3 2025, reflecting a year-on-year growth of 54% [2][68] - The report emphasizes the importance of monitoring technological advancements and the positioning of leading companies in the tumor gene testing sector [2] Summary by Sections 1. Tumor Gene Testing Industry Overview - The tumor gene testing sector is experiencing rapid growth, with significant stock price increases for leading companies such as Natera (52%), Exact Science (78%), Guardant (221%), and Grail (464%) in 2025 [2][6] - The market is projected to expand significantly, with potential market sizes for early screening (multi-cancer MCED and colorectal cancer) estimated at $40-50 billion, MRD at $15-20 billion, and companion diagnostics/treatment guidance at $3-5 billion [11][12] 2. Exact Sciences: Colorectal Cancer Screening Leader - Exact Sciences has established a robust medical ecosystem with a testing capacity exceeding 10 million annually. Its core product, Cologuard, has a brand recognition rate of over 90% [18] - The company anticipates maintaining a revenue growth rate of 15% and aims for an adjusted EBITDA margin exceeding 20% by 2027 [18][24] - Cologuard's future growth drivers include rescreening, addressing care gaps, pricing increases for the Plus version, and expanding into younger demographics [45][48] 3. Natera: Leader in MRD Testing - Natera's MRD product, Signatera, is pivotal in assessing treatment efficacy and guiding clinical decisions, with a significant focus on ctDNA mutation detection [2][68] - The company is expanding its presence in women's health and organ health, while also entering the colorectal cancer screening market [2][68] 4. Domestic Company Landscape and Investment Recommendations - The report highlights the innovative developments from domestic companies such as Aide Biology, BGI, and Mirxes, which are making strides in lung cancer MRD products and multi-cancer early screening [2] - The report suggests monitoring the technological advancements and market positioning of these domestic leaders as the industry evolves [2]